ERBB2 and breast carcinoma: Lapatinib (trade name: Tykerb®), an HER2 tyrosine kinase inhibitor, is currently being used in patients with HER2 overexpressing breast carcinomas, which have shown progressive response to trastuzumab administration [113,117].